Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epidermal growth factor receptor (EGFR)
Pharma
J&J's Rybrevant moves into first line in lung cancer subtype
While Takeda's Exkivity is out of the picture, ArriVent BioPharma and AstraZeneca spinout Dizal are each working on EGFR lung cancer meds.
Angus Liu
Mar 4, 2024 11:13am
AZ touts lung cancer advances for Tagrisso, ADC
Feb 20, 2024 1:09pm
AZ's Tagrisso combo shows edge, but survival data leave doubts
Sep 10, 2023 10:05pm
J&J notches Rybrevant trial win as Tagrisso showdown nears
Sep 6, 2023 11:35am
Takeda's Exkivity, a rival to J&J, fails in lung cancer trial
Jul 31, 2023 10:33am
ASCO: Merck's Keytruda, Roche's Tecentriq add to I-O failures
Jun 6, 2023 8:19am